PLRX Stock Price, Pliant Therapeutics Inc Quote, Chart

Market Summary

USD11.900.00

Market Closed

0.00%

PLRX Stock Price

View Fullscreen

PLRX RSI Chart

PLRX Valuation

Market Cap

716.8M

Price/Earnings (Trailing)

-4.44

Price/Sales (Trailing)

453.7

Price/Free Cashflow

-6.11

PLRX Price/Sales (Trailing)

PLRX Profitability

Return on Equity

-34.07%

Return on Assets

-31.5%

Free Cashflow Yield

-16.36%

PLRX Fundamentals

PLRX Revenue

Revenue (TTM)

1.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

PLRX Earnings

Earnings (TTM)

-161.3M

Earnings Growth (Yr)

-17.25%

Earnings Growth (Qtr)

0.91%

Breaking Down PLRX Revenue

Last 7 days

-2.4%

Last 30 days

-15.8%

Last 90 days

-30.6%

Trailing 12 Months

-58.5%

How does PLRX drawdown profile look like?

PLRX Financial Health

Current Ratio

17.72

Debt/Equity

0.02

Debt/Cashflow

-11.57

PLRX Investor Care

Shares Dilution (1Y)

2.20%

Diluted EPS (TTM)

-2.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	9.8M	5.0M	3.5M	1.6M
2022	6.6M	9.8M	9.7M	9.7M
2021	15.1M	13.2M	10.0M	7.6M
2020	53.2M	49.4M	45.6M	41.8M
2019	0	0	0	57.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pliant Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 23, 2024	cummings keith lamont	acquired	-	-	55,250	chief financial officer
Jan 23, 2024	coulie bernard	acquired	-	-	128,150	president and ceo
Jan 23, 2024	ouimette mike	acquired	-	-	31,500	general counsel & corp. sec'y
Jan 23, 2024	cheung lily	acquired	-	-	26,000	chief human resource officer
Jan 23, 2024	lefebvre eric	acquired	-	-	42,900	chief medical officer
Jan 23, 2024	hull hans	acquired	-	-	31,500	chief business officer
Jan 17, 2024	hull hans	sold	-168,613	17.23	-9,786	chief business officer
Jan 17, 2024	ouimette mike	sold	-89,544	17.23	-5,197	general counsel & corp. sec'y
Jan 17, 2024	cummings keith lamont	sold	-168,527	17.23	-9,781	chief financial officer
Jan 17, 2024	coulie bernard	sold	-443,173	17.23	-25,721	president and ceo

Which funds bought or sold PLRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	-198,000	566,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.18	-117,000	28,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	22,957	539,932	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-16,000	-	-%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	unchanged	-	-193	894	-%
Apr 05, 2024	GAMMA Investing LLC	added	95.00	223	581	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 04, 2024	Mass General Brigham, Inc	new	-	4,301,480	4,301,480	7.53%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	140	579	960	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.09	4,451,180	55,522,900	-%

Are Funds Buying or Selling PLRX?

Are funds buying PLRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PLRX

No. of Funds

Unveiling Pliant Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	blue owl capital holdings lp	5.02%	3,004,199	SC 13G
Feb 14, 2024	price t rowe associates inc /md/	6.3%	3,788,116	SC 13G
Feb 14, 2024	deep track capital, lp	9.60%	5,750,000	SC 13G/A
Feb 14, 2024	first light asset management, llc	6.07%	3,634,510	SC 13G
Feb 14, 2024	third rock ventures iii, l.p.	0.6%	339,160	SC 13G/A
Feb 14, 2024	redmile group, llc	4.5%	2,696,648	SC 13G/A
Feb 13, 2024	vanguard group inc	5.12%	3,065,869	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	laurion capital management lp	5.98%	3,583,567	SC 13G
Jan 25, 2024	blackrock inc.	8.0%	4,801,517	SC 13G

Recent SEC filings of Pliant Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Mar 12, 2024	8-K	Current Report
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	8-K	Current Report
Feb 27, 2024	S-8	Employee Benefits Plan
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Pliant Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.92	14.56	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.12	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Pliant Therapeutics Inc News

Latest updates

Pliant Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-	-	-	248	1,332	1,965	1,482	4,989	1,249	1,999	1,610	1,789	2,174	4,465	4,814	3,600	28,938	-
Operating Expenses	-1.4%	47,037	47,685	47,576	43,427	39,365	33,429	34,631	29,460	26,598	28,723	24,693	25,093	23,481	21,475	20,576	17,930	-
S&GA Expenses	-9.7%	13,854	15,346	14,574	14,154	14,251	8,823	8,296	8,579	7,846	7,671	5,475	6,566	5,627	4,591	3,040	4,011	-
R&D Expenses	2.6%	33,183	32,339	33,002	29,273	25,114	24,606	26,335	20,881	18,752	21,052	19,218	18,527	17,854	16,884	17,536	13,919	-
Interest Expenses	1.1%	321	317	319	311	317	301	173	-	-	-	-	-	-	-	-	-	-
Net Income	0.9%	-41,109	-41,487	-41,192	-37,548	-35,060	-30,615	-29,546	-28,100	-24,531	-27,045	-22,831	-22,856	-19,027	-16,534	-17,001	11,029	42,169
Net Income Margin	-133.1%	-102.11*	-43.80*	-28.73*	-13.59*	-12.73*	-11.61*	-11.09*	-15.42*	-12.85*	-9.14*	-6.14*	-5.01*	-	-	-	-	-
Free Cashflow	30.7%	-25,163	-36,318	-25,362	-30,439	-31,405	-19,194	-24,650	-21,142	-20,457	-22,990	-20,042	-13,907	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-5.2%	512	540	575	598	351	377	185	197	221	234	256	275	296	312	329	119
Current Assets	-5.4%	506	534	566	588	340	366	174	185	209	229	251	271	291	308	324	112
Cash Equivalents	9.6%	63.00	58.00	55.00	103	34.00	45.00	25.00	33.00	52.00	45.00	35.00	51.00	51.00	55.00	178	86.00
Net PPE	-10.1%	4.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	3.1%	39.00	37.00	42.00	36.00	37.00	40.00	37.00	23.00	22.00	14.00	12.00	11.00	12.00	12.00	13.00	9.00
Current Liabilities	4.1%	29.00	27.00	30.00	23.00	24.00	26.00	23.00	18.00	17.00	13.00	11.00	10.00	12.00	11.00	12.00	8.00
Long Term Debt	0.3%	10.00	10.00	10.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-5.9%	474	503	533	562	313	337	148	174	199	220	244	264	283	300	316	-
Retained Earnings	-9.0%	-499	-458	-417	-375	-338	-303	-272	-243	-215	-190	-163	-140	-117	-98.80	-82.27	-76.29
Additional Paid-In Capital	1.0%	973	964	952	939	654	643	422	418	414	411	408	405	401	399	398	-
Shares Outstanding	0.1%	60.00	60.00	59.00	59.00	49.00	40.00	36.00	36.00	36.00	36.00	36.00	36.00	-	-	-	-
Float	-	-	-	1,008	-	-	-	282	-	-	-	752	-	-	-	856	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	30.7%	-25,102	-36,224	-24,759	-30,276	-31,239	-18,498	-24,396	-20,498	-19,865	-22,510	-19,403	-13,665	-16,485	-15,792	7,772	-12,766	-	-	-
Share Based Compensation	-11.7%	9,152	10,362	13,046	11,923	10,855	4,809	3,403	3,531	2,768	2,811	2,280	2,578	1,515	1,169	786	425	-	-	-
Cashflow From Investing	-16.6%	31,921	38,253	-22,978	-174,208	20,022	-178,252	6,495	1,531	25,783	32,100	3,584	12,232	11,906	-105,080	-106,319	-11,373	-	-	-
Cashflow From Financing	-68.7%	219	699	161	273,326	284	216,297	10,426	-153	516	449	192	1,370	237	-2,365	163,640	51,700	-	-	-

PLRX Income Statement

2023-12-31

Statements of Operations and Comprehensive Gain (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 1,580	$ 9,685	$ 7,572
Operating expenses:
Research and development	(127,797)	(96,936)	(77,549)
General and administrative	(57,928)	(39,949)	(27,558)
Total operating expenses	(185,725)	(136,885)	(105,107)
Loss from operations	(184,145)	(127,200)	(97,535)
Interest and other income (expense), net	24,076	4,670	272
Interest expense	(1,267)	(791)	0
Net loss	$ (161,336)	$ (123,321)	$ (97,263)
Earnings Per Share [Abstract]
Basic (USD per share)	$ (2.75)	$ (2.94)	$ (2.71)
Diluted (USD per share)	$ (2.75)	$ (2.94)	$ (2.71)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Basic (in shares)	58,719,083	42,015,908	35,846,421
Diluted (in shares)	58,719,083	42,015,908	35,846,421
Comprehensive loss:
Net loss	$ (161,336)	$ (123,321)	$ (97,263)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Net unrealized gain (loss) on short-term investments	2,303	(1,757)	(169)
Total other comprehensive gain (loss)	2,303	(1,757)	(169)
Comprehensive loss	$ (159,033)	$ (125,078)	$ (97,432)

PLRX Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 63,234	$ 33,685
Short-term investments	431,011	297,502
Accounts receivable	0	1,983
Tax credit receivable	0	83
Prepaid expenses and other current assets (Note 5)	11,257	7,058
Total current assets	505,502	340,311
Property and equipment, net	3,567	4,486
Operating lease right-of-use assets	1,211	5,422
Restricted cash	1,482	0
Other non-current assets	392	394
Total assets	512,154	350,613
Current liabilities
Accounts payable	4,531	1,580
Accrued research and development	12,456	11,218
Accrued liabilities (Note 6)	10,219	8,658
Lease liabilities, current	1,318	2,457
Total current liabilities	28,524	23,913
Lease liabilities, non-current	0	3,429
Long-term debt (Note 7)	10,054	9,929
Total liabilities	38,578	37,271
Commitments and Contingencies (Note 13)
Stockholders’ equity
Preferred stock, $0.0001 par value 10,000,000 shares authorized at December 31, 2023 and 2022, none issued or outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2023 and 2022; and 59,921,002 and 48,941,254 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively;	6	5
Additional paid-in capital	972,973	653,707
Accumulated deficit	(499,748)	(338,412)
Accumulated other comprehensive gain (loss)	345	(1,958)
Total stockholders’ equity	473,576	313,342
Total liabilities and stockholders’ equity	$ 512,154	$ 350,613

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avÃƒÅ¸6 and avÃƒÅ¸1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avÃƒÅ¸1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avÃƒÅ¸8 and avÃƒÅ¸1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

CEO	Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.
WEBSITE	https://pliantrx.com
INDUSTRY	Biotechnology
EMPLOYEES	155

Pliant Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Pliant Therapeutics Inc? What does PLRX stand for in stocks?

PLRX is the stock ticker symbol of Pliant Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pliant Therapeutics Inc (PLRX)?

As of Thu Apr 25 2024, market cap of Pliant Therapeutics Inc is 716.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLRX stock?

You can check PLRX's fair value in chart for subscribers.

What is the fair value of PLRX stock?

You can check PLRX's fair value in chart for subscribers. The fair value of Pliant Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pliant Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PLRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pliant Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PLRX is over valued or under valued. Whether Pliant Therapeutics Inc is cheap or expensive depends on the assumptions which impact Pliant Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLRX.

What is Pliant Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, PLRX's PE ratio (Price to Earnings) is -4.44 and Price to Sales (PS) ratio is 453.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLRX PE ratio will change depending on the future growth rate expectations of investors.